{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:19:12Z","timestamp":1762431552043,"version":"3.37.3"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T00:00:00Z","timestamp":1542844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T00:00:00Z","timestamp":1542844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"crossref","award":["116020"],"award-info":[{"award-number":["116020"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s40263-018-0581-x","type":"journal-article","created":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T09:12:28Z","timestamp":1542877948000},"page":"1085-1090","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer\u2019s Disease"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0093-5773","authenticated-orcid":false,"given":"Jacoline C.","family":"Bouvy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pall","family":"Jonsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"O\u2019Rourke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella Santuccione","family":"Chadha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niklas","family":"Hedberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amr","family":"Makady","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Entela","family":"Xoxi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine Gispen-de","family":"Wied","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"Schiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raj","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Gallacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,22]]},"reference":[{"issue":"2","key":"581_CR1","first-page":"109","volume":"4","author":"J Cummings","year":"2017","unstructured":"Cummings J, Fox N. Defining disease modifying therapy for Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2017;4(2):109\u201315.","journal-title":"J Prev Alzheimers Dis."},{"key":"581_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13195-017-0312-4","volume":"9","author":"CW Richie","year":"2017","unstructured":"Richie CW, Russ TC, Banerjee S, et al. The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer\u2019s disease. Alzheimer\u2019s Res Ther. 2017;9:85.","journal-title":"Alzheimer\u2019s Res Ther."},{"issue":"6","key":"581_CR3","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1080\/13543784.2017.1323868","volume":"26","author":"D Mehta","year":"2017","unstructured":"Mehta D, Jackson R, Paul G, Shi J, Sabbagh M. Why do trials for Alzheimer\u2019s disease drugs keep failing? A discontinued drug perspective for 2010-2015. Expert Opin Investig Drugs. 2017;26(6):735\u20139.","journal-title":"Expert Opin Investig Drugs"},{"key":"581_CR4","unstructured":"ROADMAP. Advisory group. Available from: \n                  https:\/\/roadmap-alzheimer.org\/expert-advisory-group\/\n                  \n                . Accessed 2 Jan 2018."},{"key":"581_CR5","unstructured":"International Consortium for Health Outcomes Measurement. What are outcomes? Available from: \n                  http:\/\/www.ichom.org\/frequently-asked-questions\/\n                  \n                . Accessed 2 Jan 2018."},{"key":"581_CR6","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2147\/CIA.S11718","volume":"5","author":"AT Isik","year":"2010","unstructured":"Isik AT. Late onset Alzheimer\u2019s disease in older people. Clin Interv Aging. 2010;5:307\u201311.","journal-title":"Clin Interv Aging"},{"key":"581_CR7","unstructured":"National Institute for Health and Care Excellence. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer\u2019s disease. Technology appraisal TA217. Published 23 March 2011; last updated 11 May 2016. \n                  https:\/\/www.nice.org.uk\/guidance\/ta217\n                  \n                . Accessed 2 Jan 2018."},{"key":"581_CR8","unstructured":"European Medicines Agency. Memantine scientific discussion. London, 15 November 2005. EMEA\/H\/C\/463\/II\/15. \n                  http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Scientific_Discussion_-_Variation\/human\/000463\/WC500058762.pdf\n                  \n                . Accessed 2 Jan 2018."},{"key":"581_CR9","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jalz.2015.06.1893","volume":"12","author":"ER Siemers","year":"2016","unstructured":"Siemers ER, Sundell KL, Carlson C, et al. Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer\u2019s disease patients. Alzheimers Dement. 2016;12:110\u201320.","journal-title":"Alzheimers Dement."},{"key":"581_CR10","unstructured":"Nelson M, Smith M, Ly A, et al. Combined report: D2.3 Stakeholder generated lists of priority RWE relevant outcomes and D2.4 Disease progression and outcomes classification matrix. 2018. \n                  https:\/\/roadmap-alzheimer.org\/wp-content\/uploads\/2018\/07\/ROADMAP_D2.3D2.4.pdf\n                  \n                . Accessed 10 Jan 2018."},{"key":"581_CR11","doi-asserted-by":"crossref","unstructured":"Makady A, van Veelen A, Jonsson P, et al. Using real-world data in health technology assessment (HTA) practice: a comparative study of five HTA agencies. Pharmacoeconomics. 2018;36(3):359\u2013368.","DOI":"10.1007\/s40273-017-0596-z"},{"issue":"4","key":"581_CR12","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.jval.2016.12.003","volume":"20","author":"A Makady","year":"2017","unstructured":"Makady A, ten Ham R, de Boer A, Hillege H, Klungel O, Goettsch W. Policies for use of real-world data in health technology assessment (HTA): a comparative study of six HTA agencies. Value Health. 2017;20(4):520\u201332.","journal-title":"Value Health"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-018-0581-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-018-0581-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-018-0581-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T02:21:54Z","timestamp":1604110914000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-018-0581-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,22]]},"references-count":12,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["581"],"URL":"https:\/\/doi.org\/10.1007\/s40263-018-0581-x","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"type":"print","value":"1172-7047"},{"type":"electronic","value":"1179-1934"}],"subject":[],"published":{"date-parts":[[2018,11,22]]},"assertion":[{"value":"22 November 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The activities reported in this article were conducted as part of the ROADMAP project. This project has received funding for the Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreement No. 116020. The views and opinions expressed in this article are those of the authors only and cannot be understood as being made on behalf of, or reflecting the position or view of any of the authors\u2019 employing organisations. This article is not intended to replace or complement official guidelines that may be in place or in development. The open access fee was paid for by the ROADMAP project.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jacoline C. Bouvy, Pall Jonsson, Diana O\u2019Rourke, Niklas Hedberg, Amr Makady, Entela Xoxi, Christine Gispen-de Wied, Anja Schiel, Raj Long and John Gallacher have no conflicts of interest directly relevant to the contents of this article (other than those specified under Funding). Antonella Santuccione Chadha is an employee of Roche Diagnostics.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}